Shlomo Yanai: The IDF Major General Who Ran Teva at Its Peak

By The Olam Editorial Team · Jun 27, 2026

IDF Major General, commander Gaza Division and Southern Command, lead of the IDF Camp David 2000 delegation. CEO of Makhteshim Agan 2003–2007. CEO of Teva Pharmaceuticals 2007–2012 during peak years (closed Barr at $7.46B, Cephalon at $6.8B). Chairman of The Phoenix Holdings.

The Builders | Olam.business

Published Jun 27, 2026.

Shlomo Yanai (born 1952) is the Israeli executive whose arc runs from IDF Major General — commanding the Gaza Division and Southern Command, leading the Israeli military delegation to the 2000 Camp David negotiations — to CEO of Makhteshim Agan (the agro-chemicals giant later rebranded as ADAMA) and then CEO of Teva Pharmaceuticals during its peak market-capitalization years. He later chaired the Phoenix Holdings insurance group. The military-to-C-suite arc is one of the canonical Israeli executive patterns; Yanai is its most consequential example.

The Teva chapter is the defining one. Yanai served as CEO from 2007 to 2012 — the period when Teva was the largest single Israeli-headquartered listed company by market capitalization, the dominant global generic-pharmaceutical operator, and one of the most institutionally significant Israeli corporate positions of the post-2000 era. He took the company through the major Barr Pharmaceuticals acquisition (closed 2008) and through the Cephalon acquisition (closed 2011) — the deals that defined Teva's global generic-and-specialty positioning.

Yanai is also one of the more publicly discreet Israeli executives of his generation. He has rarely given long-form interviews, has not built a post-Teva public-speaking profile, and operates as a senior corporate director rather than as a public figure. The Phoenix chairmanship has continued the institutional Israeli corporate-leadership pattern.

Snapshot

Born	1952, Israel
IDF career	Major General · commander of the Gaza Division · commander of Southern Command · head of the IDF Strategic Planning Branch · led the Israeli military delegation to the 2000 Camp David negotiations
First civilian CEO role	Makhteshim Agan (now ADAMA) — CEO 2003–2007 · Israeli agro-chemicals giant
Teva Pharmaceuticals CEO	2007–2012 · during Teva's peak market-capitalization years
Major Teva acquisitions under Yanai	Barr Pharmaceuticals ($7.46B, closed 2008) · Cephalon ($6.8B, closed 2011)
Subsequent senior role	Chairman of The Phoenix Holdings — major Israeli insurance and financial services group
Education	Tel Aviv University · further graduate training at U.S. military and business institutions
Operating posture	Discreet · institutional · rare public speaker

The IDF Career

Yanai's military career covered the operational and strategic ranks of the Israeli Defense Forces over more than three decades. He served as commander of the IDF's Gaza Division during the period that anchored the Israeli security architecture in the Strip through the late 1990s. He subsequently commanded the IDF Southern Command — one of the three principal regional commands of the Israeli military, responsible for the Sinai, Negev, and Gaza-adjacent theatres. He served as head of the IDF Strategic Planning Branch.

Yanai led the IDF delegation to the 2000 Camp David II negotiations between Ehud Barak and Yasser Arafat under Bill Clinton's mediation — the negotiations that produced no agreement but that defined the operational and territorial parameters around which subsequent Israeli political and security thinking has been organized. The Camp David delegation role placed Yanai inside the small group of Israeli senior officers who carry both an operational military record and a high-level strategic-negotiations record.

He retired from active military service in the early 2000s as a Major General — the senior IDF rank below Lieutenant General (the Chief of the General Staff) — and transitioned into the corporate executive track.

Makhteshim Agan

Yanai's first major civilian CEO position was at Makhteshim Agan — the Israeli agro-chemicals giant, today known as ADAMA Agricultural Solutions. He served as CEO from 2003 to 2007, during the company's expansion in the global generic-crop-protection category. The role gave him a four-year operating record in a complex global-industrial company before he was recruited to Teva.

Makhteshim Agan was historically owned by the Israeli Koor Industries conglomerate. The company was sold to Chinese ChemChina in stages through the 2010s and rebranded as ADAMA. Yanai's CEO tenure pre-dated the ChemChina transition.

The Teva Chapter

Yanai was appointed CEO of Teva Pharmaceuticals in March 2007, succeeding the long-tenured Israel Makov. He led Teva through what remains the company's peak market-capitalization period — the years 2007 to 2012, when Teva was the largest Israeli-headquartered listed company by market value and the dominant global generic-pharmaceutical operator.

The defining transactions of his tenure were two major acquisitions. In July 2008, Teva closed the $7.46 billion acquisition of Barr Pharmaceuticals, the U.S. generic-drug specialist — the largest pharmaceutical acquisition by any Israeli-headquartered company at the time. In October 2011, Teva closed the $6.8 billion acquisition of Cephalon, the specialty-pharmaceutical company. Together the two deals expanded Teva from a pure-generic operator into a generic-and-specialty pharmaceutical platform, and cemented its position as one of the world's largest pharmaceutical companies by prescription volume.

Yanai stepped down as CEO in May 2012 and was succeeded by Jeremy Levin. The subsequent Teva trajectory — the leverage from the Allergan generics acquisition in 2016, the post-Copaxone patent cliff, the multi-year debt-reduction cycle, the executive succession through Erez Vigodman, Yitzhak Peterburg, Kåre Schultz, and now Richard Francis — sits outside the Yanai tenure. The company Yanai handed off was at the top of its global market position.

The Phoenix and Subsequent Roles

After Teva, Yanai served as Chairman of The Phoenix Holdings — one of the major Israeli insurance and financial-services groups, alongside Migdal (controlled by Shlomo Eliahu), Harel (anchored by the Hamburger family), and Clal Insurance. The Phoenix has been one of the active strategic-positioning institutions in Israeli finance through the 2010s and into the 2020s. Yanai's chairmanship continued the institutional Israeli corporate-leadership pattern that had defined his Teva tenure.

He has also held board and advisory positions across Israeli industry and a number of public-policy and educational institutions.

Why Yanai Matters in Israel

Three reasons.

First — the military-to-C-suite arc. The pattern of Israeli senior officers transitioning from IDF general-officer ranks into senior civilian executive roles is one of the structural features of the Israeli economy. Yanai is one of the canonical examples — Major General, Camp David delegation lead, then CEO of two of the country's largest listed companies in succession. Few other Israeli executives have carried the full version of this arc to the same scale.

Second — the Teva CEO tenure during peak years. Teva at its peak (2010–2012) had a market capitalization north of $50 billion and was the single largest Israeli-headquartered listed company. Running a global pharmaceutical platform of that scale from Israeli headquarters, with the regulatory, capital, and operational complexity that implies, is a distinct executive accomplishment. The Barr and Cephalon deals are case studies in their own right.

Third — the discreet operating posture. Israeli CEOs at the global-company scale often build substantial public-speaking and policy-advocacy profiles after their operating tenures. Yanai has not. The continued institutional corporate-director presence (Phoenix chairmanship, board positions) without a parallel public-figure profile is structurally unusual at his level of executive seniority.

Yanai's Key Roles

IDF Major General · commander Gaza Division · commander Southern Command · head IDF Strategic Planning Branch
Lead of the IDF delegation to the 2000 Camp David II negotiations
CEO of Makhteshim Agan (now ADAMA) 2003–2007
CEO of Teva Pharmaceuticals 2007–2012
Chairman of The Phoenix Holdings (insurance and financial services)
Board positions and advisory roles across Israeli industry and public-policy institutions

Yanai's Legacy and Influence

The Yanai arc is one of the most institutionally significant Israeli executive trajectories of the past two decades. The IDF Major General who runs the country's largest listed pharmaceutical company at its global peak, then chairs one of its largest insurance groups, while remaining publicly discreet, is a distinct executive pattern. The Camp David delegation role places Yanai inside the senior Israeli strategic-thinking class as well — the small group of Israelis with both operational military and high-level strategic-negotiations experience.

For the Israeli senior-executive class, Yanai is one of the canonical references. The IDF-to-corporate transition has produced a long list of executives at varying scales; Yanai is at the top of that list by company scale, by sustained tenure, and by the structural complexity of the businesses he ran.

Why Yanai Matters Now

In 2026, with the Israeli insurance and pharmaceutical categories navigating their respective regulatory cycles (Solvency II at the insurance level, the Teva debt-reduction cycle and the broader Israeli pharmaceutical category), Yanai's continued institutional presence at The Phoenix and across Israeli corporate boards is part of the senior-Israeli-executive layer that the next generation of CEOs is built against.

The Israeli senior-executive class is also reshaping. The post-October 7 environment has surfaced a new generation of Israeli executives navigating a more politically and operationally complex global business environment. The Yanai-era operating playbook — discreet, institutional, focused on operating execution rather than public profile — is one of the references that generation is studied against.

FAQ

Who is Shlomo Yanai?
Shlomo Yanai (born 1952) is the Israeli executive who served as CEO of Teva Pharmaceuticals from 2007 to 2012, during the company's peak global market-capitalization years. He previously served as a Major General in the Israel Defense Forces — commanding the Gaza Division and Southern Command and leading the IDF delegation to the 2000 Camp David negotiations — and as CEO of Makhteshim Agan (now ADAMA) from 2003 to 2007. He subsequently chaired The Phoenix Holdings insurance group.

What was Yanai's military career?
Yanai served as a Major General in the IDF. He commanded the IDF Gaza Division, the IDF Southern Command, and headed the IDF Strategic Planning Branch. He led the Israeli military delegation to the 2000 Camp David II negotiations between Ehud Barak and Yasser Arafat under Bill Clinton's mediation.

When did Yanai serve as CEO of Teva?
Shlomo Yanai served as CEO of Teva Pharmaceuticals from March 2007 to May 2012. He succeeded Israel Makov and was succeeded by Jeremy Levin.

What major acquisitions did Teva make under Yanai?
Two principal transactions defined Yanai's CEO tenure at Teva. In July 2008, Teva closed the $7.46 billion acquisition of Barr Pharmaceuticals. In October 2011, Teva closed the $6.8 billion acquisition of Cephalon. The two deals expanded Teva from a pure-generic operator into a generic-and-specialty pharmaceutical platform.

What was Yanai's role at Makhteshim Agan?
Yanai served as CEO of Makhteshim Agan — the Israeli agro-chemicals giant now known as ADAMA Agricultural Solutions — from 2003 to 2007. The role was his first senior civilian CEO position after retiring from the IDF, and pre-dated his recruitment to Teva.

What is The Phoenix Holdings?
The Phoenix Holdings is one of the major Israeli insurance and financial-services groups, sitting alongside Migdal (controlled by Shlomo Eliahu), Harel (anchored by the Hamburger family), and Clal Insurance. Yanai served as Chairman after his Teva tenure.

Why is Yanai's career considered structurally significant?
Yanai is one of the canonical examples of the Israeli military-to-C-suite arc. The combination — IDF Major General with operational and strategic-negotiations experience, then CEO of two of the largest Israeli listed companies in succession, then chairman of a major insurance group — is one of the most institutionally significant Israeli executive trajectories of the past two decades.

שלמה ינאי: מאלוף בצה"ל למנכ"ל טבע ויו"ר הפניקס

יליד 1952. אלוף בצה"ל. שירת כמפקד אוגדת עזה, מפקד פיקוד הדרום, וראש אגף תכנון בצה"ל. עמד בראש המשלחת הצבאית הישראלית למשא ומתן בקמפ דייוויד השני בשנת 2000.

לאחר פרישה מצה"ל, שימש מנכ"ל מכתשים אגן (כיום אדמה) בין 2003 ל-2007, ולאחר מכן מנכ"ל טבע תעשיות פרמצבטיות בין 2007 ל-2012 — בתקופת השיא של שווי השוק של החברה. בתקופת כהונתו השלימה טבע את רכישת בר פרמצבטיקלס בעלות 7.46 מיליארד דולר (2008) ואת רכישת ספאלון בעלות 6.8 מיליארד דולר (2011).

לאחר טבע שימש יו"ר הפניקס אחזקות — קבוצת הביטוח והפיננסים הישראלית הגדולה. המעבר מצה"ל לתפקידי מנכ"ל בכירים הוא אחד הדפוסים הקאנונים של המנהיגות העסקית בישראל, וינאי הוא הדוגמה הברורה ביותר שלו.

The Olam Editorial Team | The Builders / הבונים